Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats

Laboratory Investigation

Volumn 92, Issue 12, 2012, Pages 1777-1787

  Li, Yin Ji ^a   Kukita, Akiko ^b   Watanabe, Toshiyuki ^a   Takano, Toshio ^a   Qu, Pengfei ^a   Sanematsu, Keisuke ^a   Ninomiya, Yuzo ^a   Kukita, Toshio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

adjuvant arthritis; bone destruction; calcium oscillation; NDGA; NFATc1; RANKL

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NORDIHYDROGUAIARETIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE DESTRUCTION; CALCIUM SIGNALING; CONTROLLED STUDY; DISEASE SEVERITY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; NFATC TRANSCRIPTION FACTORS; NORDIHYDROGUAIARETIC ACID; OSTEITIS; OSTEOCLASTS; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84870465696     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.134     Document Type: Article

References (49)

1. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289: 1504-1508.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
3. Gravallese EM, Harada Y, Wang JT, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-951.
4. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
5. Li YJ, Kukita A, Teramachi J, et al. A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats. Lab Invest 2009;89:26-37.
6. Toh K, Kukita T, Wu Z, et al. Possible involvement of MIP-1alpha in the recruitment of osteoclast progenitors to the distal tibia in rats with adjuvant-induced arthritis. Lab Invest 2004;84:1092-1102.
7. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20: 345-357.
8. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007;1116:227-237.
9. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-269.
10. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
11. Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161:1419-1427.
12. Harada H, Nakayama T, Nanaka T, et al. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm Res 2004;53:45-52.
13. Itoh F, Aoyagi S, Kusama H, et al. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation 2004;28:15-21.
14. Herrak P, Gortz B, Hayer S, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004;50:2327-2337.
15. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-1699.
16. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-1427.
17. Arteaga S, Andrade-Cetto A, Cardenas R. Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol 2005; 98:231-239.
18. Youngren JF, Gable K, Penaranda C, et al. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005; 94:37-46.
19. Ryan CJ, Zavodovskaya M, Youngren JF, et al. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate 2008;68:1232-1240.
20. Watanabe T, Kukita T, Kukita A, et al. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J Endocrinol 2004;180:193-201.
21. Kukita A, Kukita T, Shin JH, et al. Induction of mononuclear precursor cells with osteoclastic phenotypes in a rat bone marrow culture system depleted of stromal cells. Biochem Biophys Res Commun 1993;196:1383-1389.
22. Kukita A, Kukita T, Hata K, et al. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells. Bone Miner 1993;23:113-127.
23. Kukita T, Kukita A, Nagata K, et al. Novel cell-surface Ag expressed on rat osteoclasts regulating the function of the calcitonin receptor. J Immunol 1994;153:5265-5273.
24. Kukita T, Kukita A, Xu L-X, et al. Successful detection of active osteoclasts in situ by systemic administration of an osteoclast-specific monoclonal antibody. Calcif Tissue Int 1998;63:148-153.
25. Kukita T, Kukita A, Xu L-X, et al. Kat1-antigen-a reliable immuno-logical marker for identifying osteoclast precursors of rats: detection of subpopulations among precursors and initiation of osteocla-stogenesis. Histochem Cell Biol 2001;115:215-222.
26. Rahman MM, Kukita A, Kukita T, et al. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003;101: 3451-3459.
27. Kuratani T, Nagata K, Kukita T, et al. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 1998;13:751-759.
28. Hossain A, Zheng CL, Kukita A, et al. Balance of Th1/Th2 cytokines associated with the preventive effect of incomplete Freund's adjuvant on the development of adjuvant arthritis in LEW rats. J Autoimmun 2001;17:289-295.
29. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009;64:823-839.
30. Kusner EJ, Marks RL, Aharony D, et al. Inhibition by REV-5901 of leukotriene release from guinea-pig and human lung tissue in vitro. Biochem Pharmacol 1989;38:4183-4189.
31. Lebeau A, Esclaire F, Rostene W, et al. Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity. Neuroreport 2001;12:2199-2202.
32. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
33. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-1269.
34. Matsumoto M, Kogawa M, Wada S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279:45969-45979.
35. Crotti TN, Flannery M, Walsh NC, et al. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006;372:92-102.
36. Kim K, Lee SH, Ha Kim J, et al. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 2008;22:176-185.
37. Kukita T, Wada N, Kukita A, et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004;200:941-946.
38. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005;20:653-662.
39. Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001;276:49343-49349.
40. David JP, Sabapathy K, Hoffmann O, et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 2002;115(Pt 22):4317-4325.
41. Koga T, Inui M, Inoue K, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004; 428:758-763.
42. 2+]i oscillation regulation. Genes Dev 2007;21:1803-1816.
43. Culver CA, Michalowski SM, Maia RC, et al. The anti-apoptotic effects of nordihydroguaiaretic acid: inhibition of cPLA(2) activation during TNF-induced apoptosis arises from inhibition of calcium signaling. Life Sci 2005;77:2457-2470.
44. Wiegert JS, Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium 2011;49: 296-305.
45. Meyer GE, Chesler L, Liu D, et al. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem 2007;102:1529-1541.
46. Jeon SB, Ji KA, You HJ, et al. Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun 2005;328:595-600.
47. Eads D, Hansen R, Oyegunwa A, et al. Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. J Inflamm (Lond) 2009;6:2.
48. Nakamura T, Kukita T, Shobuike T, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-5816.
49. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8:707-717.